NDRA Stock: From $2.31 To $2.40 (3.9% Increase) Pre-Market Explanation

By Amit Chowdhry ● May 4, 2021
  • The stock price of ENDRA Life Sciences Inc (NASDAQ: NDRA) increased from $2.31 to $2.40 (up 3.9%) pre-market. This is why it happened.

The stock price of ENDRA Life Sciences Inc (NASDAQ: NDRA) increased from $2.31 to $2.40 (up 3.9%) pre-market. Investors are responding positively to ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS), announcing the company has recently been issued U.S. Patent 10993624 (the ‘624 patent) “Systems And Methods For Thermoacoustic Transducer Optimization” and U.S. Patent 10996163 (the ‘163 patent) “Acoustically Isolated Thermoacoustic Imaging Probe and Process of Manufacture” from the United States Patent & Trademark Office (USPTO).

The TAEUS transducer serves to receive thermoacoustic ultrasound signals. And the ‘624 patent provides a tool for developing and adjusting the TAEUS probe and its transducer functionality to maximize the amount of information extracted from a subject.

The ‘163 patent relates to the thermoacoustic probe used in ENDRA’s TAEUS system. And in particular, the ‘163 patent protects ENDRA’s proprietary probe and manufacturing process to acoustically isolate the radiofrequency element from the transducer element, thereby reducing signal noise and improving signal clarity.

ENDRA’s commercialization of TAEUS includes establishing clinical research partnerships worldwide – with an initial focus on Europe and the U.S. To date the company has established six research partnerships, including 3 in Europe and 3 in the U.S. In December 2020, ENDRA had renewed its collaboration agreement with the GE Healthcare unit of General Electric Company, extending the agreement’s term by two years to December 2022. 


“These issued patents support ENDRA’s goal to develop applications for our proprietary TAEUS technology in areas of high unmet clinical need and with no practical existing tools. They represent a key step forward in the development of optimized hybrid ultrasound and thermoacoustic imaging systems for a wide range of clinical applications, including Non-Alcoholic Fatty Liver Disease (NAFLD). We remain committed to growing and protecting our valuable intellectual property in priority global markets. Our IP portfolio currently stands at 85 assets, which we define as patents issued, filed, licensed or in preparation.”

— ENDRA’s Chief Executive Officer Francois Michelon

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.